Genmab — November 2024
-
small new trial - Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders https://clinicaltrials.gov/study/NCT06672705
-
https://ash.confex.com/ash/2024/webprogram/start.html#srch=words|epcoritamab|method|and|pge|1|byDayany|any|bySymposiumany|any|byAudienceany|any ASH abstracts available. Getting 64 hits when searching for epcoritamab... good luck...
-
Here you can find the SITC abstracts https://jitc.bmj.com/content/12/Suppl_2
-
Gen1042: Conclusions DuoBody-CD40×4-1BB demonstrated biologic and early antitumor activity with a favorable safety profile in patients with advanced solid tumors. Expansion cohorts, including combination therapy with PD-1 inhibitors, are currently enrolling.
-
SITC24 Acasunlimab https://jitc.bmj.com/content/12/Suppl_2/A821 & https://jitc.bmj.com/content/12/Suppl_2/A752
-
SITC24 Duo
Body -EpCAMx4-1BB (BNT314/GEN1059) https://jitc.bmj.com/content/12/Suppl_2/A833 -
SITC24 Traverse Biotech is developing TB-Bs1, a CD3xROR2 bispecific antibody generated using the DuoBody(R) platform, https://jitc.bmj.com/content/12/Suppl_2/A1185
-
SITC24 The combination of HexaBody
-OX40 with PD-(L)1 blockade potentiates agonistic activity in vitro and antitumor activity in vivo -GEN1055
https://jitc.bmj.com/content/12/Suppl_2/A842 -
Thank you E L. I don't understand half of it, but it at least seems positive. What I don't understand is why Biontech opted out. Is there anything in those links indicating why that could be?
-
My question is about Acasunlimab (should you have any doubts).
-
No. I think you have to see it in the light of this, from Biontech results: (“R&D”) expenses were €550.3 million for the three months ended September 30, 2024, compared to €497.9 million for the comparative prior year period. For the nine months ended September 30, 2024, R&D expenses were €1,642.4 million, compared to €1,205.3 million for the comparative prior year period.
-
Ok, so a cost cutting exercise which hopefully turns out to be a bad decision for them.
-
Thank you.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind